Parecoxib Description

Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 careful inhibitor in the aforementioned class as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively if patients are clumsy to yield articulate medications. It is accustomed through abundant of Europe for abbreviate appellation perioperative affliction ascendancy abundant in the aforementioned way ketorolac (Toradol) is used in the United States. In 2005, the U.S. Food and Biologic Administering (FDA) issued a letter of non-approval for parecoxib in the United States.

Parecoxib is an amide prodrug of the cyclooxygenase II (COX-2) selective, non-steroidal anti-inflammatory biologic (NSAID) valdecoxib, with anti-inflammatory, analgesic, and antipyretic activities. Upon administration, parecoxib is hydrolyzed by hepatic carboxyesterases to its active form, valdecoxib. Valdecoxib selectively binds to and inhibits COX-2. This prevents the about-face of arachidonic acid into prostaglandins, which are complex in the adjustment of pain, inflammation, and fever. This NSAID does not arrest COX-1 at ameliorative concentrations and, therefore, does not baffle with blood coagulation.